Back to News
Market Impact: 0.2
Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026
Source: globenewswire.com
Healthcare & Biotech
In a five-patient Phase 1b Crohn's disease cohort, mean endoscopic disease activity fell 47.5% and mean fecal calprotectin fell 58.8% after 14 days. The early results are encouraging but come from a small cohort and short observation period.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- A top medical technology stock is trading at a big discount. Here's why I'm buying
- Obsessed with CoreWeave and the AI trade? You're missing out on some great stocks
- UnitedHealthcare and Humana are ending Medicare Advantage plans for nearly 1 million people
- Why is Intuitive Surgical stock sliding today?
- Disc Medicine prices $450 million stock offering at $75/share
- Alpha Teknova stock tumbles on public offering announcement